Stock Selection: Muse Spark 1.1's picks for 2026-10-16
Muse Spark 1.1 picked REGN, MANH, NOW, CEG, MRNA for a 1-day horizon. Portfolio return vs SPY: +0.55%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-16 |
| Measured to | 2026-10-19 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +0.55% |
| Picks that beat SPY | 60% |
| Benchmark return | -0.15% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | REGN | -1.65% | 71% | -1.50% | No |
| 2 | MANH | -0.07% | 68% | +0.08% | Yes |
| 3 | NOW | +1.75% | 64% | +1.90% | Yes |
| 4 | CEG | -3.18% | 62% | -3.03% | No |
| 5 | MRNA | +5.17% | 55% | +5.32% | Yes |
The model's market view
SPY is flat into mid-October with rotation out of crowded megacap into quality healthcare, vertical software and nuclear power tied to AI data center demand. Fresh analyst actions on Oct 15 (UBS on REGN, Morgan Stanley on MANH, TD Cowen on NOW, CIBC on CEG) are driving pre-market gaps that have held, suggesting under-positioning. One-session trade favors following these upgrade-driven momentum names over broad market.
Why each pick
REGN
UBS upgraded to Buy from Neutral and raised target $660 to $978 on Oct 15 citing Dupixent long-term opportunity, the strongest large-cap biopharma catalyst of the day. Stock held $792-806 range with 50-day MA $791.59 support, 3.6% upgrade day shows demand. Q3 results Oct 30 provide further catalyst, valuation still 22% below new target. Risk: trading near 52-week high $859, could mean-revert if healthcare rotation fades.
MANH
Morgan Stanley upgraded to Overweight from Equalweight, target $180 to $250 on Oct 15, analyst Chris Quintero, citing accelerating cloud bookings and AI agentic tools. Stock hit new 1-year high, +4% pre-market, closed $226.96 holding above $218. Cloud transition and CEO Eric Clark GTM changes drive estimate revisions. Risk: +69.5% in 6 months and elevated P/E 61x may cause exhaustion.
NOW
TD Cowen raised target $140 to $165 Buy on Oct 15 ahead of Q3 results Oct 28, citing ITSM Prime upgrades and federal strength. Stock rose 6.2% on upgrade, part of enterprise software rotation after YTD -6.8% underperformance. cRPO growth is key test, AI governance push broadens TAM. Risk: high beta and rates sensitivity, if SPY sells off software lags.
CEG
CIBC initiated with Outperformer $358 on Oct 15 covering 4 IPPs (TLN, VST, CEG, NRG) by analyst Mark Jarvi, driven by long-term nuclear contracts with hyperscalers and Google PPA. Nuclear pure-play scarcity makes initiations powerful for flows. AI data center power demand is secular tailwind. Risk: valuation stretched and correlated to power price volatility.
MRNA
Contrarian momentum inclusion: Goldman target raise $120 to $137 Neutral on Oct 15 tied to intismeran Phase 3 melanoma data at ESMO Oct 24, stock up 9.9% 5-day, 48% 1-month, 632% YTD showing massive momentum that tends to persist into medical conferences. While target is below spot, flow and short squeeze can drive outperformance vs SPY for one session. Risk: extremely overbought, 52-week high $227.46 resistance, failure to hold $208 low could reverse quickly.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-6 | URBN, FOX, GDX, FITB, CLF | +0.91% | 20% |
| Gemini 3 Pro | BAC, GS, XLF, MS, TSM | -0.55% | 20% |
| Perplexity | WMT, KMX, CROX, FOX, SMTC | -0.92% | 20% |
| Grok 4 | AA, FOXA, JPM, EAT, ZETA | -2.46% | 0% |
| DeepSeek | KMX, FTRE, FTAI, NVST, CROX | -1.38% | 20% |
Written up on ForecastNest Insights: Stock Selection: Muse Spark 1.1's picks for 2026-10-16.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.